Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.34 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | STAT3 | P40763 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10073234 | 0.82 | KMT2A (0.49) | ALDH1A1CYP2C9CYP2C19NPSR1KMT2A | |
| SCHEMBL22032247 | 0.81 | SRC (0.42) | ALDH1A1IGF1RCYP2C9CYP2C19NPSR1 | |
| SCHEMBL22032165 | 0.80 | NR1H4 (0.39) | CYP2C9CYP2C19NPSR1KMT2ACA12 | |
| SCHEMBL879308 | 0.80 | ALDH1A1 (0.48) | ALDH1A1L3MBTL1KMT2ACA12CA1 | |
| SCHEMBL19695468 | 0.79 | HPGD (0.48) | ALDH1A1KMT2AALDH1A3ALDH3A1CA12 | |
| SCHEMBL21957323 | 0.79 | AAK1 (0.38) | CYP2C9CYP2C19NPSR1KMT2ACA12 | |
| SCHEMBL22032148 | 0.76 | CNR1 (0.35) | CYP2C9CYP2C19NPSR1KMT2ACA12 | |
| SCHEMBL14254820 | 0.76 | MAPK1 (0.42) | CYP2C9CYP2C19NPSR1KMT2ACA12 | |
| SCHEMBL29954570 | 0.76 | ATR (0.47) | ALDH1A1L3MBTL1CA12CA1CA2 | |
| SCHEMBL17048749 | 0.75 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1ALDH1A3MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518763-B2 | Macrocyclic compound and use thereof | SCOHIA PHARMA, INC. (JP) | 2022-12-06 | — | — | US | disclosed |
| US-11518763-B2 | Macrocyclic compound and use thereof | SCOHIA PHARMA, INC. (JP) | 2022-12-06 | — | — | US | disclosed |
| US-20220119391-A1 | MACROCYCLIC COMPOUND AND USE THEREOF | SCOHIA PHARMA, INC. (JP) | 2022-04-21 | — | — | US | disclosed |
| US-20220119391-A1 | MACROCYCLIC COMPOUND AND USE THEREOF | SCOHIA PHARMA, INC. (JP) | 2022-04-21 | — | — | US | disclosed |
| EP-3890738-A1 | MACROCYCLIC COMPOUND AND USE THEREOF | Scohia Pharma, Inc. (JP) | 2021-10-13 | — | — | EP | disclosed |
| CN-113164468-A | Macrocyclic compounds and uses thereof | 思可海雅药品公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020116660-A1 | MACROCYCLIC COMPOUND AND USE THEREOF | SCOHIA PHARMA, INC. (JP) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020116660-A1 | MACROCYCLIC COMPOUND AND USE THEREOF | SCOHIA PHARMA, INC. (JP) | 2020-06-11 | — | — | WO | disclosed |
| US-10669242-B2 | Clostridium difficile toxin inhibitors | Venenum Biodesign, LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190194147-A1 | Novel Clostridium Difficile Toxin Inhibitors | Venenum Biodesign, LLC (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2017214359-A1 | NOVEL CLOSTRIDIUM DIFFICILE TOXIN INHIBITORS | VENENUM BIODESIGN LLC (US) | 2017-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518763-B2 | Macrocyclic compound and use thereof | TFAM, KEAP1, FASTKD1 | ALDH1A1 730/4885L3MBTL1 2255/4885IGF1R 2110/4885 |
| US-20190194147-A1 | Novel Clostridium Difficile Toxin Inhibitors | GABRA5, GABRA1, GABRA4 | ALDH1A1 2381/4885L3MBTL1 4588/4885IGF1R 4512/4885 |
| US-10669242-B2 | Clostridium difficile toxin inhibitors | GABRA5, GABRA1, GABBR2 | ALDH1A1 1908/4885L3MBTL1 4542/4885IGF1R 4631/4885 |
| US-20220119391-A1 | MACROCYCLIC COMPOUND AND USE THEREOF | TFAM, KEAP1, CKMT1A; CKMT1B | ALDH1A1 714/4885L3MBTL1 2412/4885IGF1R 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.